Drug intelligence / Profile preview

FKC889

Development stage: Unknown
Lead developer: Fosun Pharma
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

FKC889 is a CD19-targeted CAR-T cell therapy developed for the treatment of adult patients with relapsed or refractory indolent non-Hodgkin lymphoma, as well as other B-cell malignancies such as mantle cell lymphoma and precursor B-cell acute lymphoblastic leukemia. It is administered intravenously and currently in clinical trials in China[1][2][3]. The mechanism of action involves genetically engineered T cells expressing a chimeric antigen receptor (CAR) that targets CD19 on malignant B cells, leading to their destruction[2].

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on FKC889.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FKC889.

Explore the full profile